ARC-EX has a defined U.S. device pathway for hand sensation and strength; it is not authorized as a universal paralysis cure. The FDA clearance dated November 14, 2025 includes use with functional task practice in clinics and take-home exercises at home. 1
The exact benefit language matters. “Hand strength and sensation” should not automatically become “restored hand function,” “reversed paralysis” or “repaired the spinal cord.” FDA's original assessment contains explicit limitations on broader conclusions. 2
What is the device?
ARC-EX delivers programmed transcutaneous electrical spinal stimulation. Its electrodes contact intact skin rather than being implanted around the spinal cord. The home-use document describes operation by rehabilitation professionals in medical centers and by patients or assisting people at home, within the prescription-use pathway. 1
This description does not establish that a consumer stimulation product sold for another purpose is equivalent to ARC-EX. Shared use of electricity is not shared authorization, clinical evidence or a validated treatment protocol.
Who is in the indicated population?
The home-use indication specifies ages 18–75, a chronic non-progressive deficit and an incomplete spinal cord injury from C2 through C8. The intended improvement is hand sensation and strength, with the stated practice or exercise context. 1
That is substantially narrower than “people with spinal cord injuries.” Injury level, completeness and disease course are part of the evidence boundary. This article reports them but does not assess an individual's eligibility or supply treatment settings.
What did FDA say about the evidence?
The original De Novo review notes that observed probable benefits accompanied intensive outpatient rehabilitation. It identifies the single-arm, within-person, open-label design as a limitation in separating device effects from ongoing rehabilitation. It also states that functional benefits and neurological recovery were not demonstrated, and that persistence beyond adjunctive use was unknown. 2
This is the part of the record that a broad “paralysis reversed” headline loses. A before-and-after improvement can be real while attribution remains uncertain. The agency's assessment should not be replaced by either promotional language or an equally unsupported claim that nothing useful happened.
Strength, function and neurological recovery are not synonyms
A strength measure can change without establishing a specified daily task. A task can become possible with equipment without establishing a change in neurological injury classification. Those are different levels of claim.
The FDA review specifically distinguishes the evidence it accepted from demonstrations of neurological recovery. 2
For an evidence history, the right response is to retain separate fields. That allows a later study to add a new kind of benefit without making it appear that the older study had already proved it. The assistance-versus-recovery explainer provides the terminology.
What changed with home use?
The November 2025 510(k) record expands the use setting to include the home with take-home exercises. It preserves the same intended population and strength/sensation purpose. The clearance is not a new demonstration that every broader function improved. 1
A change in delivery setting can still matter practically. It addresses where the authorized system can be used. But usability, access and effectiveness should remain separate questions rather than be collapsed into one “new approval” claim.
This page does not provide a local provider list, a coverage determination or a verified consumer price. Those facts are not supplied by the clearance document.
What the next evidence would need to add
A stronger causal comparison could better distinguish the contribution of stimulation from concurrent rehabilitation. Defined functional outcomes could establish whether changes translate into particular everyday abilities. Observation after stopping adjunctive use could address persistence.
These are our interpretation of the evidence gaps identified in the FDA record—not a statement that a new study has already resolved them. 2
How ARC-EX differs from a brain–spine interface
A brain–spine interface uses decoded brain activity as part of a control system for stimulation. That is a different architecture from the ARC-EX use described in the clearance. The 2023 walking report concerns a separate research demonstration. 3 1
The defensible present conclusion is specific: ARC-EX's authorized strength-and-sensation use and home setting are real regulatory facts; generalized neurological recovery is not established by those documents.